{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:24:23Z","timestamp":1791606263611,"version":"4.3.4"},"reference-count":111,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"am","delay-in-days":289,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Auris Nasus Larynx"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.anl.2023.08.005","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T09:11:37Z","timestamp":1695373897000},"page":"371-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Pathogenesis-based application of biologics for chronic rhinosinusitis: Current and future perspectives"],"prefix":"10.1016","volume":"51","author":[{"given":"Mitsuhiro","family":"Okano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Kanai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3648-2879","authenticated-orcid":false,"given":"Aiko","family":"Oka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anl.2023.08.005_bib0001","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4193\/Rhin20.601","article-title":"Executive summary of EPOS 2020 including integrated care pathways","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.anl.2023.08.005_bib0002","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/all.13042","article-title":"Nasal and sinus symptoms and chronic rhinosinusitis in a population-based sample","volume":"72","author":"Hirsch","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0003","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.alit.2019.07.002","article-title":"Eosinophilic chronic rhinosinusitis","volume":"68","author":"Fujieda","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.anl.2023.08.005_bib0004","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.alit.2020.11.010","article-title":"Health-related quality of life and drug treatment satisfaction were low and correlated negatively with symptoms in patients with severe refractory chronic rhinosinusitis with nasal polyps","volume":"70","author":"Okano","year":"2021","journal-title":"Allergol Int"},{"key":"10.1016\/j.anl.2023.08.005_bib0005","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jaip.2022.03.002","article-title":"Chronic rhinosinusitis with nasal polyps: quality of life in the biologics era","volume":"10","author":"Mullo","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anl.2023.08.005_bib0006","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/alr.22740","article-title":"Rhinologic disease and its impact on sleep: a systematic review","volume":"11","author":"Fried","year":"2021","journal-title":"Int Forum Allery Rhinol"},{"key":"10.1016\/j.anl.2023.08.005_bib0007","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anl.2023.08.005_bib0008","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4193\/Rhin17.255","article-title":"The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps","volume":"57","author":"Khan","year":"2018","journal-title":"Rhinology"},{"key":"10.1016\/j.anl.2023.08.005_bib0009","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/lary.26391","article-title":"Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis","volume":"127","author":"DeConde","year":"2017","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anl.2023.08.005_bib0010","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1111\/all.13874","article-title":"Oral corticosteroid use, morbidity and mortality in asthma: a nationwide prospective cohort study in Sweden","volume":"74","author":"Ekstrom","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0011","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1477-7525-7-36","article-title":"Validation of abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications","volume":"7","author":"Bharmal","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.anl.2023.08.005_bib0012","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/all.13712","article-title":"Treatment satisfaction in atopic dermatitis relates to patient-reported severity: a cross-sectional study","volume":"74","author":"Nakahara","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0013","doi-asserted-by":"crossref","first-page":"e2705","DOI":"10.1590\/1518-8345.0745.2705","article-title":"Satisfaction with medication in coronary disease treatment: psychometrics of the Treatment Satisfaction Questionnaire for Medication","volume":"24","author":"Liberato","year":"2016","journal-title":"Rev Lat Am Enfermagem"},{"key":"10.1016\/j.anl.2023.08.005_bib0014","first-page":"66","article-title":"Relationship of the treatment satisfaction to health-related quality of life among Palestinian patients with type 2 diabetes mellitus","volume":"2","author":"Zyoud","year":"2015","journal-title":"J Clin Transl Endocrinol"},{"key":"10.1016\/j.anl.2023.08.005_bib0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/03007995.2016.1251891","article-title":"Early patient experience with montelukast orally disintegrating tablets in Japan: a cross-sectional survey of treatment satisfaction in patients with asthma and\/or allergic rhinitis","volume":"33","author":"Whalley","year":"2017","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.anl.2023.08.005_bib0016","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1172\/JCI124611","article-title":"Precision medicine and phenotypes, endotypes, genotypes, regiotypes, and theratypes and allergic diseases","volume":"129","author":"Adache","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.anl.2023.08.005_bib0017","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1111\/all.12644","article-title":"Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC study","volume":"70","author":"Tokunaga","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0018","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1034\/j.1398-9995.2000.00090.x","article-title":"Survey of recognition and utilization of guidelines for the diagnosis and management of bronchial asthma in Japan","volume":"55","author":"Makino","year":"2000","journal-title":"Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0019","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.1365-2222.2012.04015.x","article-title":"COX\/PGE2 axis critically regulates effects of LPS on eosinophilia-associated cytokine production in nasal polyps","volume":"42","author":"Higaki","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0020","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1508749","article-title":"Innate immunity and asthma risk in Amish and Hutterite farm children","volume":"375","author":"Stein","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2023.08.005_bib0021","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13601-017-0157-8","article-title":"Endotype-driven treatment in chronic upper airway diseases","volume":"7","author":"De Greve","year":"2017","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0022","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1084\/jem.183.6.2593","article-title":"T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines","volume":"183","author":"Fossiez","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.anl.2023.08.005_bib0023","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.jaip.2019.05.009","article-title":"Associations between inflammatory endotypes and clinical presentations in chronic rhinosinusitis","volume":"7","author":"Stevens","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anl.2023.08.005_bib0024","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.alit.2014.12.006","article-title":"Immunopathology of chronic rhinosinusitis","volume":"64","author":"Kato","year":"2015","journal-title":"Allergol Int"},{"key":"10.1016\/j.anl.2023.08.005_bib0025","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.alit.2015.01.004","article-title":"Association and management of eosinophilic inflammation in upper and lower airways","volume":"64","author":"Okano","year":"2015","journal-title":"Allergol Int"},{"key":"10.1016\/j.anl.2023.08.005_bib0026","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/lary.23786","article-title":"Periostin may play a protective role in the development of eosinophilic chronic rhinosinusitis with nasal polyps in a mouse model","volume":"123","author":"Kim","year":"2013","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anl.2023.08.005_bib0027","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/all.12054","article-title":"Local receptor revision and class switching to IgE in chronic rhinosinusitis with nasal polyps","volume":"68","author":"Gevaert","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0028","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.jaci.2009.01.047","article-title":"Prostaglandin E2 suppresses staphylococcal enterotoxin-induced eosinophilia-associated cellular responses dominantly through an E-prostanoid 2-mediated pathway in nasal polyps","volume":"123","author":"Okano","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0029","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2332\/allergolint.14-OA-0703","article-title":"Cellular responses to Staphylococcus aureus alpha-toxin in chronic rhinosinusitis with nasal polyps","volume":"63","author":"Okano","year":"2014","journal-title":"Allergol Int"},{"key":"10.1016\/j.anl.2023.08.005_bib0030","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jaci.2017.05.004","article-title":"The IL-33\/ST2 axis is crucial in type 2 airway responses induced by Staphylococcus aureus derived serine protease-like protein D","volume":"141","author":"Teufelberger","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0031","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.jaci.2014.10.058","article-title":"Staphylococcal protein A-formulated immune complexes suppress enterotoxin-induced cellular responses in nasal polyps","volume":"136","author":"Okano","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0032","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1177\/0194599812451010","article-title":"Improving the detection of fungi in eosinophilic mucin: seeing what we could not see before","volume":"147","author":"Guo","year":"2012","journal-title":"Otolaryngol head Neck Surg"},{"key":"10.1016\/j.anl.2023.08.005_bib0033","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2222.2010.03584.x","article-title":"Role of fungal antigens in eosinophilia-associated cellular responses in nasal polyps: a comparison with enterotoxin","volume":"41","author":"Okano","year":"2011","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0034","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.immuni.2018.04.023","article-title":"Amphiregulin-producing pathogenic memory T helper 2 cells instruct eosinophils to secrete osteopontin and facilitate airway fibrosis","volume":"49","author":"Morimoto","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.anl.2023.08.005_bib0035","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/ACI.0000000000000496","article-title":"Group 2 innate lymphoid cells and eosinophilic chronic rhinosinusitis","volume":"19","author":"Tojima","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0036","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jaci.2003.10.068","article-title":"Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis","volume":"113","author":"Higashi","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0037","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.jaci.2018.07.006","volume":"143","author":"Takeda","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0038","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3390\/ijms21051843","article-title":"Clinical significance of cytoplasmic IgE-positive mast cells in eosinophilic chronic rhinosinusitis","volume":"21","author":"Gion","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.anl.2023.08.005_bib0039","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.alit.2018.09.002","article-title":"Significance of IgG4-positive cells in severe eosinophilic chronic rhinosinusitis","volume":"68","author":"Koyama","year":"2019","journal-title":"Allergol Int"},{"key":"10.1016\/j.anl.2023.08.005_bib0040","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.alit.2019.12.004","article-title":"Serum IgG4 as a biomarker reflecting pathophysiology and post-operative recurrence in chronic rhinosinusitis","volume":"69","author":"Oka","year":"2020","journal-title":"Allergol Int"},{"key":"10.1016\/j.anl.2023.08.005_bib0041","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2500\/ajra.2017.31.4400","article-title":"Thrombin and activated coagulation factor X stimulate the release of cytokines and fibronectin from nasal polyp fibroblasts via protease-activated receptors","volume":"31","author":"Shimizu","year":"2017","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0042","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1164\/rccm.201207-1292OC","article-title":"Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression","volume":"187","author":"Takabayashi","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anl.2023.08.005_bib0043","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jaci.2018.03.004","article-title":"Endotype-driven care pathways in patients with chronic rhinosinusitis","volume":"141","author":"Bachert","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0044","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jaci.2010.02.020","article-title":"Oral steroids and doxycycline: two different approaches to treat nasal polyps","volume":"125","author":"Van Zele","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0045","first-page":"209","article-title":"Macrolide antibiotics protect against endotoxin-induced vascular leakage and neutrophil accumulation in rat trachea","volume":"429","author":"Culic","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.anl.2023.08.005_bib0046","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1128\/AAC.38.7.1641","volume":"38","author":"Tamaoki","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.anl.2023.08.005_bib0047","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1378\/chest.122.1.213","article-title":"Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion","volume":"122","author":"Tagaya","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.anl.2023.08.005_bib0048","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1128\/AAC.01011-06","volume":"51","author":"Hoffmann","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.anl.2023.08.005_bib0049","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaci.2013.03.048","article-title":"Long type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, with regulates Th2 cytokine production","volume":"132","author":"Doherty","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0050","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0051","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0052","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0053","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4193\/Rhin17.139","article-title":"Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together-a real life study","volume":"56","author":"Bidder","year":"2018","journal-title":"Rhinology"},{"key":"10.1016\/j.anl.2023.08.005_bib0054","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18176\/jiaci.0391","article-title":"Effectiveness of omalizumab in severe allergic asthma and nasal polyposis: a real-life study","volume":"30","author":"Tiotiu","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0055","first-page":"226","article-title":"Omalizumab in patients with NSAIDs-exacerbated respiratory disease","volume":"58","author":"Forster-Ruhrmann","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.anl.2023.08.005_bib0056","article-title":"Omolizumab is effective in nasal polyposis with or without asthma, a real-life study","volume":"15","author":"Tat","year":"2022","journal-title":"Word Allergy Organ J"},{"key":"10.1016\/j.anl.2023.08.005_bib0057","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2183\/pjab.87.463","article-title":"Interleukin-5 and IL-5 receptor in health and diseases","volume":"87","author":"Takatsu","year":"2011","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.anl.2023.08.005_bib0058","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1182\/blood-2012-05-432088","article-title":"Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans","volume":"121","author":"Ueki","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.anl.2023.08.005_bib0059","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0091-6749(92)90067-C","article-title":"The effect of recombinant human interleukin-5 on eosinophil accumulation and degranulation in human nasal mucosa","volume":"90","author":"Terada","year":"1992","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0060","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anl.2023.08.005_bib0061","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0062","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): in-depth sinus surgery analysis","volume":"13","author":"Fokkens","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0063","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.jaci.2021.10.040","article-title":"Mopolizumab for chronic rhinosinusitis with nasal polyps: treatment efficacy by comorbidity and blood eosinophil count","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0064","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1177\/19458924211009429","article-title":"A phase II, multicenter, randomized, placebo-controlled study of benralizumab, a humanized anti-IL-5R alpha monoclonal antibod, in patients with eosinophilic chronic rhinosinusitis","volume":"35","author":"Takabayashi","year":"2021","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0065","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/all.13814","article-title":"Periostin: an emerging biomarker for allergic diseases","volume":"74","author":"Izuhara","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0066","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jaci.2020.01.027","article-title":"Formation of nasal polyps: the roles of innate type 2 inflammation and deposition of fibrin","volume":"145","author":"Takabayashi","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0067","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/all.13424","article-title":"Role of IL-13R\u03b12 in modulating IL-13-induced MUC5AC and ciliary changes in healthy and CRSwNP mucosa","volume":"738","author":"Liu","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0068","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.anl.2023.08.005_bib0069","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2147\/JAA.S363527","article-title":"Improvement in health-related quality of life with dupilumab in patients with moderate-to-severe asthma with comorbid chronic rhinosinusitis with\/without nasal polyps: an analysis of the QUEST study","volume":"15","author":"Hopkins","year":"2022","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0070","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/all.14906","article-title":"Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status","volume":"77","author":"Fujieda","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0071","doi-asserted-by":"crossref","first-page":"165","DOI":"10.18176\/jiaci.0823","article-title":"Eosinophilia induced by blocking the IL-4\/IL-13 pathway: potential mechanisms and clinical outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J Invest Allergol Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0072","first-page":"e25218","article-title":"Exacerbation of eosinophilic granulatosis with polyangiitis after administering dupilumab for severe asthma and eosinophilic rhinosinusitis with nasal polyposis","volume":"14","author":"Tanaka","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.anl.2023.08.005_bib0073","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2169\/internalmedicine.7990-21","article-title":"Severe asthma where osinophilic granulatosis with polyangiitis became apparent after discontinuation of dupilumab","volume":"61","author":"Ikeda","year":"2022","journal-title":"Intern Med"},{"key":"10.1016\/j.anl.2023.08.005_bib0074","article-title":"Safety of biologics for atopic disease during pregnancy","volume":"18","author":"Shakuntulla","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anl.2023.08.005_bib0075","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40257-022-00749-1","article-title":"Development of cutaneous T-cell lymphoma following biologic treatment: a systemic review","volume":"24","author":"Schaefer","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.anl.2023.08.005_bib0076","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2332\/allergolint.11-RAI-0395","article-title":"TSLP expression: cellular sources, triggers, and regulatory mechanisms","volume":"61","author":"Takai","year":"2012","journal-title":"Allergol Int"},{"key":"10.1016\/j.anl.2023.08.005_bib0077","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/ni805","article-title":"Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP","volume":"3","author":"Soumelis","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0078","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1002\/eji.201041195","article-title":"TSLP enhances the function of helper type 2 cells","volume":"41","author":"Kitajima","year":"2011","journal-title":"Eor J Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0079","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.4049\/jimmunol.178.3.1396","article-title":"Induction of IL-4 expression in CD4(+) T cells by thymic stromal lymphopoietin","volume":"178","author":"Omori","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0080","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2023.08.005_bib0081","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s40265-022-01679-2","article-title":"Tezepelumab: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.anl.2023.08.005_bib0082","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fimmu.2017.00475","article-title":"The ST2\/IL-33 axis in immune cells during inflammatory diseases","volume":"8","author":"Griesenauer","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0083","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1164\/rccm.201212-2227OC","article-title":"IL-33-responsive innate lymphoid cells are an important source of IL-13 in chronic rhinosinusitis with nasal polyps","volume":"188","author":"Shaw","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anl.2023.08.005_bib0084","doi-asserted-by":"crossref","first-page":"E115","DOI":"10.1002\/lary.24462","article-title":"Expression of IL-33 and its receptor ST2 in chronic rhinosinusitis with nasal polyps","volume":"124","author":"Baba","year":"2014","journal-title":"Laryngoscope"},{"key":"10.1016\/j.anl.2023.08.005_bib0085","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and safety of itepekimab in patients with moderate-to-severe asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anl.2023.08.005_bib0086","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/ACI.0000000000000332","article-title":"Targeting IL-25 as a novel therapy in chronic rhinosinusitis with nasal polyps","volume":"17","author":"Lee","year":"2017","journal-title":"Curr Opin Allergy Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0087","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0281205","article-title":"Efficacy and safety of GSK3772847 in patients with moderate-to-severe asthma with allergic fungal airway disease: a phase IIa randomized, multicenter, double-blind, sponsor-open, comparative trial","volume":"18","author":"Akinseye","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.anl.2023.08.005_bib0088","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1111\/all.14809","article-title":"Efficacy and safely of treatment with biologics for severe chronic rhinosinusitis with nasal polyps: a systemic review for the EAACI guidelines","volume":"76","author":"Agache","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.anl.2023.08.005_bib0089","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.jaip.2022.02.034","article-title":"Comparison of different biologics for treating chronic rhinosinusitis with nasal polyps: a network analysis","volume":"10","author":"Cai","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anl.2023.08.005_bib0090","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000519228","article-title":"Which is the best biologics for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis","volume":"183","author":"Wu","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0091","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0092","doi-asserted-by":"crossref","first-page":"165","DOI":"10.18176\/jiaci.0823","article-title":"Eosinophilia induced by blocking the IL-4\/IL-13 pathway: potential mechanisms and clinical outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J Invest Allergol Clin Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0093","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.alit.2021.02.002","article-title":"Cycling therapy with benralizumab and dupilumab for severe eosinophilic asthma with eosinophilic chronic rhinosinusitis and eosinophilic otitis media","volume":"70","author":"Hamada","year":"2021","journal-title":"Allergol Int"},{"key":"10.1016\/j.anl.2023.08.005_bib0094","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3390\/biom12040522","article-title":"Sequential biotherapy targeting IL-5 and IL-4\/13 in patients with eisoinophilic asthma and sinusitis and otitis media","volume":"12","author":"Chikumoto","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.anl.2023.08.005_bib0095","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/alr.22944","article-title":"Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps","volume":"12","author":"Hellings","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.anl.2023.08.005_bib0096","unstructured":"https:\/\/clinicaltrials.gov."},{"key":"10.1016\/j.anl.2023.08.005_bib0097","doi-asserted-by":"crossref","first-page":"22","DOI":"10.2174\/1573398X13666170616110738","article-title":"An update on anti-IgE therapy in pediatric respiratory diseases","volume":"13","author":"Licari","year":"2017","journal-title":"Curr Respir Med Rev"},{"key":"10.1016\/j.anl.2023.08.005_bib0098","doi-asserted-by":"crossref","DOI":"10.1111\/bcp.15002","article-title":"A phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma","volume":"88","author":"Singh","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.anl.2023.08.005_bib0099","doi-asserted-by":"crossref","first-page":"12411","DOI":"10.1038\/s41598-023-39311-2","article-title":"Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4R\u03b1, for the treatment of Th2 inflammatory diseases","volume":"13","author":"Zhang","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.anl.2023.08.005_bib0100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/13543784.2023.2215425","article-title":"Investigational anti IL-13 asthma treatment: a 2023 update","volume":"32","author":"Matera","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.anl.2023.08.005_bib0101","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s13555-023-00901-7","article-title":"Nemolizumab improved patient-reported symptoms of atopic dermatitis with pruritus: post hoc analysis of a Japanese phase III randomized controlled trial","volume":"13","author":"Kabashima","year":"2023","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.anl.2023.08.005_bib0102","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/cells10010019","article-title":"Discover, function, and therapeutic targeting of Siglec-8","volume":"10","author":"Youngblood","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.anl.2023.08.005_bib0103","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1358\/dot.2023.59.3.3419557","article-title":"Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis","volume":"59","author":"Simopoulou","year":"2023","journal-title":"Drugs Today"},{"key":"10.1016\/j.anl.2023.08.005_bib0104","first-page":"1061","article-title":"Biological therapies for atopic dermatitis: an update","volume":"17","author":"Deleanu","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.anl.2023.08.005_bib0105","doi-asserted-by":"crossref","unstructured":"Verstockt B, Salas A, Sands BE, Abraham C, Leibovitzh H, Neurath MF, et\u00a0al. IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gasteroenterol Hepatol w023; 20: 433-46.","DOI":"10.1038\/s41575-023-00768-1"},{"key":"10.1016\/j.anl.2023.08.005_bib0106","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12016-019-08734-z","article-title":"Therapeutic antibodies for nasal polyposis treatment: where are we headed?","volume":"59","author":"Agarwal","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0107","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa2024257","article-title":"Efficacy and safety of itepekimab in patients with moderate-to-severe asthma","volume":"385","author":"Wechsler","year":"2021","journal-title":"N Eng J Med"},{"key":"10.1016\/j.anl.2023.08.005_bib0108","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jdermsci.2020.06.005","article-title":"Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis","volume":"99","author":"Nakagawa","year":"2020","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.anl.2023.08.005_bib0109","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/jir.2022.0211","article-title":"Anti-tumor necrosis factor for supplementary management in severe asthma: a systemic review and meta analysis","volume":"43","author":"Ahmad","year":"2023","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.anl.2023.08.005_bib0110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.888392","article-title":"Systemic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders","volume":"13","author":"Arnold","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.anl.2023.08.005_bib0111","doi-asserted-by":"crossref","first-page":"755","DOI":"10.2147\/JAA.S410592","article-title":"Effect of biologic therapies on airway hyperresponsiveness and allergic response: a systemic literature review","volume":"16","author":"Spahn","year":"2023","journal-title":"J Asthma Allergy"}],"container-title":["Auris Nasus Larynx"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814623001517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0385814623001517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T19:41:54Z","timestamp":1759952514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0385814623001517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":111,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0385814623001517"],"URL":"https:\/\/doi.org\/10.1016\/j.anl.2023.08.005","relation":{},"ISSN":["0385-8146"],"issn-type":[{"value":"0385-8146","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathogenesis-based application of biologics for chronic rhinosinusitis: Current and future perspectives","name":"articletitle","label":"Article Title"},{"value":"Auris Nasus Larynx","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anl.2023.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Japanese Society of Otorhinolaryngology-Head and Neck Surgery, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}